Fernanda Musa, MD
Gynecologic Oncology · Seattle, WANPI 1700044054
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $89,520 of the $119,849 with a category attached, or 74.7%. 18 manufacturers reported payments, led by GSK at 41.4% of the total. Among gynecologic oncology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 84 payments — averaging $1426.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$50K
- Merck$17K
- AstraZeneca$15K
- Seagen Inc.$7K
- Biontech SE$6K
- Aadi Bioscience, Inc.$6K
- plus $20K from 12 others
Across 436 payments — averaging $13,825 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aadi Bioscience, Inc.$2.6M
- GSK$2M
- Genmab U.S., Inc.$504K
- Tesaro, Inc.$378K
- Clovis Oncology, Inc.$239K
- Regeneron$162K
- plus $178K from 4 others
What the payments were for
- Consulting fees$89,52075%
- Speaking & faculty fees$14,64012%
- Travel & lodging$12,74811%
- Food & beverage$1,8542%
- Education$1,0871%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 24 | $49,656 |
| Merck | 12 | $17,470 |
| AstraZeneca | 8 | $15,264 |
| Seagen Inc. | 2 | $6,568 |
| Biontech SE | 3 | $5,660 |
| Aadi Bioscience, Inc. | 5 | $5,567 |
| Genmab U.S., Inc. | 5 | $3,961 |
| Pfizer | 1 | $3,030 |
| AbbVie | 3 | $2,550 |
| Eisai Inc. | 1 | $2,445 |
| Coopersurgical, Inc. | 2 | $2,025 |
| Clovis Oncology, Inc. | 1 | $1,700 |
| Intuitive Surgical | 8 | $1,335 |
| Eli Lilly | 2 | $1,257 |
| Astrazeneca UK Limited | 1 | $1,230 |
| Tesaro, Inc. | 1 | $61 |
| Abbott | 3 | $42 |
| Cumberland Pharmaceuticals, Inc. | 2 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$19,706
- ZEJULA$19,022
- JEMPERLI$11,600
- EPKINLY$3,935
- FYARRO$3,653
- TIVDAK$3,030
- LENVIMA$2,445
- Advincula Delineator Uterine Manipulator$2,025
- Rubraca$1,700
- DAVINCI XI$1,000
- Da Vinci Surgical System$108
How this compares
$119,849 in reported general payments places this provider in the 95th percentile of 36 gynecologic oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 14 | $255,386 |
| Prednisolone Acetate | 15 | $748 |
| Megestrol Acetate | 12 | $478 |
| Letrozole | 15 | $338 |
| Prochlorperazine Maleate | 20 | $215 |
| Ondansetron Hcl | 11 | $115 |
| Dexamethasone | 14 | $102 |
| Oxycodone Hcl | 21 | $75 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $63 |
| Ibuprofen | 12 | $34 |
| Prednisone | 11 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKZejula | $49,656 | $255,38614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 36 gynecologic oncology providers in Washington.
Other gynecologic oncology in Seattle
- Chirag ShahSeattle$732K
- Bobbie RimelSeattle$41K
- Nicole FlemingSeattle$20K
- Renata UrbanSeattle$7K
- Amy BrockmeyerSeattle$4K
- Amy BondurantSeattle$2K
- Kathryn PenningtonSeattle$2K
- Soledad JorgeSeattle$1K
- Elise SimonsSeattle$459
- Allison BarrieSeattle$428
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.